Indivior Pharmaceuticals, Inc. INDV R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.indivior.com

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Market & Price

Market Cap

$4.26B

Current Price

$36.02

High / Low (52W)

$40.61 / $12.46

Beta

1.20

Valuation

Stock P/E

18.47

Industry PE

23.65

Forward P/E

9.19

PEG Ratio

Book Value

$-1.18

Price to Book

-30.53

P/S

3.30

EV/EBITDA

9.95

Dividend Yield

Profitability & Returns

ROCE

98.95%

ROE

ROA

22.65%

Profit Margin

19.53%

Op Margin

46.06%

EPS (Latest Qtr)

$0.69

EPS (TTM)

$1.95

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.59

Current Ratio

0.86

Debt

$509.00M

Total Assets

$1.20B

Current Assets

$652.00M

Working Capital

$-262.00M

Ownership

Promoter Holding

1.43%

Chg in Prom Hold

FII / Inst Holding

106.79%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$4.73B

Total Revenue (TTM)

$1.29B

EBITDA

$475.00M

Free Cash Flow

$44.25M

Operating Cash Flow

$-111.00M

Shares Outstanding

118.20M

Gross Margin

84.96%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

11.20%

Profit 5Y

192.42%

Revenue (YoY)

19.20%

Earnings (YoY)

82.00%

PROS

Healthy ROCE of 99.0%.
Compounding revenue at 11.2% over 5 years.
Profit CAGR of 192.4% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INDV Indivior Pharmaceuticals, Inc. R2K	36.02	18.47	$4.26B	-	98.95%	-	11.20%	192.42%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	284.00M	299.00M	-	-	266.00M	302.00M	314.00M	358.00M	317.00M
Cost of Revenue	-	-	-	-	44.00M	52.00M	83.00M	67.00M	40.00M
Gross Profit	246.00M	220.00M	-	-	222.00M	250.00M	231.00M	291.00M	277.00M
Operating Expenses	-	-	-	-	155.00M	179.00M	187.00M	208.00M	140.00M
Operating Income	75.00M	-118.00M	-	-	67.00M	71.00M	44.00M	83.00M	137.00M
EBITDA	-	-	-	-	76.00M	82.00M	54.00M	92.00M	126.00M
Interest Expense	-	-	-	-	12.00M	15.00M	12.00M	6.00M	7.00M
Pretax Income	-	-	-	-	59.00M	62.00M	37.00M	81.00M	115.00M
Tax Provision	-	-	-	-	11.00M	44.00M	-5.00M	-21.00M	26.00M
Net Income	61.00M	-97.00M	-	-	47.00M	18.00M	42.00M	102.00M	89.00M
Diluted EPS	0.45	-0.72	-	-	0.38	0.14	0.33	0.79	0.69

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	901.00M	1.09B	1.19B	1.24B
Cost of Revenue	-	151.00M	174.00M	231.00M	246.00M
Gross Profit	-	750.00M	919.00M	957.00M	993.00M
Operating Expenses	-	535.00M	672.00M	723.00M	728.00M
Operating Income	-	215.00M	247.00M	234.00M	265.00M
EBITDA	-	-46.00M	-95.00M	89.00M	304.00M
Interest Expense	-	27.00M	35.00M	41.00M	45.00M
Pretax Income	-	-89.00M	-145.00M	20.00M	239.00M
Tax Provision	-	-44.00M	-19.00M	13.00M	29.00M
Net Income	-	-44.00M	-126.00M	7.00M	210.00M
Diluted EPS	-	-0.38	0.01	-0.36	1.64

Compounded Sales Growth

5 Years:	11.20%
1 Year:	19.20%

Compounded Profit Growth

5 Years:	192.42%
1 Year:	82.00%

Stock Price Performance

1 Year:	+180.09%
6 Months:	+8.82%
3 Months:	+10.09%
1 Month:	+5.48%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	1.77B	1.76B	1.32B	1.20B
Current Assets	-	1.26B	1.27B	827.00M	652.00M
Cash & Equivalents	-	774.00M	316.00M	319.00M	195.00M
Inventory	-	114.00M	135.00M	178.00M	155.00M
Receivables	-	220.00M	254.00M	254.00M	253.00M
Total Liabilities	-	1.72B	1.95B	1.65B	1.30B
Current Liabilities	-	1.02B	1.29B	924.00M	914.00M
Long Term Debt	-	237.00M	237.00M	315.00M	290.00M
Total Debt	-	277.00M	283.00M	375.00M	351.00M
Total Equity	-	51.00M	-192.00M	-337.00M	-99.00M
Shares Outstanding	-	136.48M	136.53M	124.90M	125.02M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-4.00M	-300.00M	36.00M	-27.00M
Investing Cash Flow	-	-222.00M	-95.00M	69.00M	-66.00M
Financing Cash Flow	-	-101.00M	-64.00M	-102.00M	-30.00M
Capital Expenditure	-	-5.00M	-53.00M	-31.00M	-67.00M
Free Cash Flow	-	-9.00M	-353.00M	5.00M	-94.00M
Net Change in Cash	-	-327.00M	-459.00M	3.00M	-123.00M
Share Buybacks	-	90.00M	33.00M	173.00M	11.00M

Ratios (Annual)

Figures in %.

Metric	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	83.2%	84.1%	80.6%	80.1%
Operating Margin %	-	23.9%	22.6%	19.7%	21.4%
Net Margin %	-	-4.9%	-11.5%	0.6%	16.9%
ROE %	-	-86.3%	65.6%	-2.1%	-212.1%
ROCE %	-	28.7%	52.6%	59.7%	92.3%

Shareholding Pattern

Insiders

1.43%

Institutions

106.79%

Public Float

108.34%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.21%	18.54M	$667.89M
2	Vanguard Portfolio Management LLC	6.47%	7.89M	$284.26M
3	Oaktree Capital Management LP	5.73%	6.98M	$251.57M
4	Vanguard Capital Management LLC	4.58%	5.59M	$201.23M
5	State Street Corporation	4.02%	4.90M	$176.64M
6	Two Seas Capital Lp	3.89%	4.75M	$170.97M
7	Millennium Management Llc	3.77%	4.60M	$165.53M
8	Fuller & Thaler Asset Management Inc.	3.72%	4.53M	$163.16M
9	Madison Avenue Partners, LP	3.54%	4.32M	$155.43M
10	Citadel Advisors Llc	2.93%	3.57M	$128.74M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDV

No recent headlines available.

INDV · Healthcare